Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO.
With more than 25 years of strategic and operational experience across market access, reimbursement, and government affairs, Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader. She will oversee Lucid’s rapidly expanding market access and reimbursement activities, focused on payor engagement and securing broad insurance coverage and patient access to its EsoGuard and Esophageal DNA Test.
In a statement, Lishan Aklog, MD, chairman and CEO of Lucid, commented, “Lucid is at an important inflection point as we seek to expand patient access to our groundbreaking EsoGuard test and unlock its substantial commercial opportunity. The recent extremely positive MolDX CAC meeting strengthens our confidence that Medicare coverage is within sight, and that we will be able to accelerate our ongoing positive engagements with commercial insurers on EsoGuard coverage.”
Dr. Aklog added, “We are very excited to have Danielle join the Lucid team at this critical juncture. She is a widely respected, strategically focused market access professional with a proven track record of building successful teams that have secured broad coverage for molecular diagnostic tests across the industry. Her efforts will be powered by a clinical evidence package that panelists at the CAC meeting confirmed strongly supports EsoGuard’s performance and clinical utility in detecting esophageal precancer before it progresses to cancer.”
